Skip to content

Aphea.Bio

Active
Public limited companyfounded 20169 yrs activeTechnologiepark-Zwijnaarde 21, 9052 Gent, BelgiumKBO/BCE: BE 0666.961.607
Summary

The annual accounts of Aphea.Bio for fiscal year 2025 show a net loss of 87% of total assets and of 55% of the equity at the start of that year. The 2025 annual accounts show equity of €11.45M and a net result of €-14.09M. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 66% of 191 sector peers (fiscal year 2025). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysis Watch Report Compare
Aphea.BioActiveChecked score 59/100
Risk analysis Report Compare

Checked score

Score 2025
59 / 100
Fair
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency95▼-5
Growth35▼-17
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €1k at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 5.68 against 10.45 in 2024; short-term debt: 14.9% and cash: 3.6% of total assets), and 29.5% of the assets are financed with debt.
Credit check for your own amount and term

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
70.5%
Return on assets
-86.7%
Age of the figures
9 mo
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
18202122232425
2018 to 2025 · latest year €-14.09M
neutral · A punctual record breaks
This company filed 8 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 21-08-2026, 21 days late. Weigh it accordingly: a break into the 1-to-90-day band measures 1.41% abnormal legal state, below the 1.66% market average. It is a change in behaviour, not evidence of elevated risk.
NBB · 9 filings
Deviation from the deadline
2025
21 d late
2024
41 d early
2023
13 d early
2022
11 d early
2021
27 d early
2020
58 d early
2019
21 d early
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover
€14k▼ 38.6%
2024 · €23k
2024: €23k 2025: €14k▼ -38.6% vs 2024
2024 → 2025
EBIT margin
-106965.5%▼ 40973.0pp
2024 · -65992.5%
2024: -65992.5% 2025: -106965.5%▼ -62.1% vs 2024
2024 → 2025
Net result
€-14.09M▲ 3.1%
2024 · €-14.54M
2018: €-2.18Mhighest value 2020: €-3.94M 2021: €-5.83M▼ -48.2% vs 2020 2022: €-7.79M▼ -33.6% vs 2021 2023: €-11.88M▼ -52.4% vs 2022 2024: €-14.54M▼ -22.4% vs 2023lowest value 2025: €-14.09M▲ +3.1% vs 2024
2018 → 2025
Working capital
€11.29M▼ 55.1%
2024 · €25.14M
2018: €2.44Mlowest value 2020: €4.66M 2021: €14.05M▲ +202% vs 2020 2022: €4.91M▼ -65.1% vs 2021 2023: €15.00M▲ +205% vs 2022 2024: €25.14M▲ +67.6% vs 2023highest value 2025: €11.29M▼ -55.1% vs 2024
2018 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Turnover€23k€14k▼ 38.6% 2024: €23k 2025: €14k▼ -38.6% vs 2024
Equity€13.08M-€5.29M▼ 59.6%€16.54M▲ 213%€25.53M▲ 54.4%€11.45M▼ 55.2% 2021: €13.08M 2022: €5.29M▼ -59.6% vs 2021lowest in 5 years 2023: €16.54M▲ +213% vs 2022 2024: €25.53M▲ +54.4% vs 2023highest in 5 years 2025: €11.45M▼ -55.2% vs 2024
Operating result€-6.09M-€-8.09M▼ 32.9%€-12.72M▼ 57.2%€-15.18M▼ 19.3%€-15.10M▲ 0.5% 2021: €-6.09Mhighest in 5 years 2022: €-8.09M▼ -32.9% vs 2021 2023: €-12.72M▼ -57.2% vs 2022 2024: €-15.18M▼ -19.3% vs 2023lowest in 5 years 2025: €-15.10M▲ +0.5% vs 2024
Net result€-5.83M-€-7.79M▼ 33.6%€-11.88M▼ 52.4%€-14.54M▼ 22.4%€-14.09M▲ 3.1% 2021: €-5.83Mhighest in 5 years 2022: €-7.79M▼ -33.6% vs 2021 2023: €-11.88M▼ -52.4% vs 2022 2024: €-14.54M▼ -22.4% vs 2023lowest in 5 years 2025: €-14.09M▲ +3.1% vs 2024
Result per fiscal year
Operating resultNet result
€-20.00M€-15.00M€-10.00M€-5.00M€0Operating result 2021: €-6.09M€-6.09MNet result 2021: €-5.83M€-5.83MOperating result 2022: €-8.09M€-8.09MNet result 2022: €-7.79M€-7.79MOperating result 2023: €-12.72M€-12.72MNet result 2023: €-11.88M€-11.88MOperating result 2024: €-15.18M€-15.18MNet result 2024: €-14.54M€-14.54MOperating result 2025: €-15.10M€-15.10MNet result 2025: €-14.09M€-14.09M20212022202320242025€-20M€-15M€-10M€-5M€0Operating result 2023: €-12.72M€-13MNet result 2023: €-11.88M€-12MOperating result 2024: €-15.18M€-15MNet result 2024: €-14.54M€-15MOperating result 2025: €-15.10M€-15MNet result 2025: €-14.09M€-14M202320242025
The operating result stays negative: a loss of €15.10M in 2025 against €15.18M in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €16.24M
Fixed assets €2.54M ▼ 0.8%
Current assets €13.70M ▼ 50.7%
Equity and liabilities €16.24M
Equity €11.45M ▼ 55.2%
Debt €4.80M ▼ 0.5%
Debt's share of the balance-sheet total rises from 15.9% to 29.5%. Equity and debt are lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€-2.07M▲
2024 · €-2.53M
Cash flow
€-1.06M▲
2024 · €-1.90M
Current ratio
5.68▼
2024 · 10.45
Debt to equity
0.42▲
2024 · 0.19
ROE
-123.1%▼
2024 · -57.0%
ROA
-86.7%▼
2024 · -47.9%
Interest coverage
-248.03▲
2024 · -908.78
Debt ≤ 1 year
€2.41M▼
2024 · €2.66M
Income taxes
€-528k▲
2024 · €-589k
Staff costs
€6.10M▲
2024 · €5.48M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 69 lines
Balance sheet Code20242025
Assets
Total assets20/58€30.36M€16.24M▼
Fixed assets21/28€2.56M€2.54M▼
Intangible fixed assets21€124k€94k▼
Tangible fixed assets22/27€2.02M€1.73M▼
Plant, machinery and equipment23€1.90M€1.56M▼
Furniture and vehicles24€72k€58k▼
Other tangible fixed assets26€47k€39k▼
Assets under construction and advance payments27€0€66k▲
Financial fixed assets28€417k€718k▲
Other financial fixed assets284/8€417k€718k▲
Amounts receivable and cash guarantees285/8€417k€718k▲
Current assets29/58€27.80M€13.70M▼
Amounts receivable after more than one year29€3.39M€3.16M▼
Other amounts receivable291€3.39M€3.16M▼
Stocks and contracts in progress3€0€0=
Amounts receivable within one year40/41€2.39M€2.09M▼
Trade receivables40€292k€106k▼
Other amounts receivable41€2.10M€1.99M▼
Current investments50/53€20.81M€7.57M▼
Other investments51/53€20.81M€7.57M▼
Cash at bank and in hand54/58€949k€581k▼
Deferred charges and accrued income490/1€261k€297k▲
Equity and liabilities
Total equity and liabilities10/49€30.36M€16.24M▼
Equity10/15€25.53M€11.45M▼
Contributions10/11€51.96M€51.96M=
Capital10€51.96M€51.96M=
Issued capital100€51.96M€51.96M=
Profit (loss) carried forward14€-26.42M€-40.51M▼
Amounts payable17/49€4.82M€4.80M▼
Amounts payable within one year42/48€2.66M€2.41M▼
Trade debts44€1.40M€1.76M▲
Suppliers440/4€1.40M€1.76M▲
Taxes, remuneration and social security45€1.26M€658k▼
Taxes450/3€743k€7k▼
Remuneration and social security454/9€522k€651k▲
Accrued charges and deferred income492/3€2.16M€2.38M▲
Income statement Code20242025
Operating income70/76A€13.41M€14.31M▲
Turnover70€23k€14k▼
Own construction capitalised72€12.11M€12.44M▲
Other operating income74€1.27M€1.85M▲
Operating charges60/66A€28.59M€29.41M▲
Goods for resale, raw materials and consumables60€0-
Purchases600/8€0-
Services and other goods61€10.43M€10.25M▼
Remuneration, social security and pensions62€5.48M€6.10M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€12.65M€13.03M▲
Provisions for liabilities and charges: additions (uses and reversals)635/8€0-
Other operating charges640/8€26k€27k▲
Operating profit (loss)9901€-15.18M€-15.10M▲
Financial income75/76B€83k€509k▲
Recurring financial income75€83k€509k▲
Income from financial fixed assets750-€3k
Income from current assets751€80k€488k▲
Other financial income752/9€3k€18k▲
Financial charges65/66B€37k€24k▼
Recurring financial charges65€37k€24k▼
Debt charges650€3k€8k▲
Other financial charges652/9€34k€16k▼
Profit (loss) for the period before taxes9903€-15.13M€-14.62M▲
Income taxes67/77€-589k€-528k▲
Taxes670/3€49k€387▼
Tax adjustments and reversals of tax provisions77€639k€529k▼
Profit (loss) for the period9904€-14.54M€-14.09M▲
Profit (loss) for the period to be appropriated9905€-14.54M€-14.09M▲
Appropriation of the result
Profit (loss) to be appropriated9906€-26.42M€-40.51M▼
Profit (loss) brought forward from the previous period14P€-11.88M€-26.42M▼
Transfer from equity791/2€0-
From contributions791€0-
Social balance
Average headcount (FTE)908756.656.9▲

The notes to these accounts (60 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Accounts by statement
Line20212022202320242025Change
Operating income70/76A---€13.41M€14.31M▲ 6.7%
Turnover70---€23k€14k▼ 38.6%
Own construction capitalised72---€12.11M€12.44M▲ 2.7%
Other operating income74---€1.27M€1.85M▲ 45.5%
Operating charges60/66A---€28.59M€29.41M▲ 2.9%
Goods for resale, raw materials and consumables60---€0--
Purchases600/8---€0--
Services and other goods61---€10.43M€10.25M▼ 1.7%
Remuneration, social security and pensions62€2.46M€3.62M€4.75M€5.48M€6.10M▲ 11.3%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€470k€347k€10.00M€12.65M€13.03M▲ 3.0%
Provisions for liabilities and charges: additions (uses and reversals)635/8-€9k€-9k€0--
Other operating charges640/8€1k€4k€4k€26k€27k▲ 2.5%
Gross operating margin9900€-3.15M€-4.11M€2.03M---
Operating profit (loss)9901€-6.09M€-8.09M€-12.72M€-15.18M€-15.10M▲ 0.5%
Financial income75/76B€697€667€150k€83k€509k▲ 510%
Recurring financial income75€697€667€150k€83k€509k▲ 510%
Income from financial fixed assets750----€3k-
Income from current assets751---€80k€488k▲ 510%
Other financial income752/9---€3k€18k▲ 432%
Financial charges65/66B€17k€46k€98k€37k€24k▼ 34.2%
Recurring financial charges65€17k€46k€98k€37k€24k▼ 34.2%
Debt charges650---€3k€8k▲ 200%
Other financial charges652/9---€34k€16k▼ 53.6%
Profit (loss) for the period before taxes9903€-6.10M€-8.13M€-12.67M€-15.13M€-14.62M▲ 3.4%
Income taxes67/77€-268k€-342k€-787k€-589k€-528k▲ 10.3%
Taxes670/3---€49k€387▼ 99.2%
Tax adjustments and reversals of tax provisions77---€639k€529k▼ 17.2%
Profit (loss) for the period9904€-5.83M€-7.79M€-11.88M€-14.54M€-14.09M▲ 3.1%
Profit (loss) for the period to be appropriated9905€-5.83M€-7.79M€-11.88M€-14.54M€-14.09M▲ 3.1%
Line20212022202320242025Change
Assets
Total assets20/58€15.92M€7.34M€19.90M€30.36M€16.24M▼ 46.5%
Fixed assets21/28€858k€900k€2.46M€2.56M€2.54M▼ 0.8%
Intangible fixed assets21€110k€6k€42k€124k€94k▼ 23.9%
Tangible fixed assets22/27€487k€634k€2.00M€2.02M€1.73M▼ 14.5%
Plant, machinery and equipment23€424k€580k€1.91M€1.90M€1.56M▼ 17.7%
Furniture and vehicles24€39k€41k€56k€72k€58k▼ 19.7%
Other tangible fixed assets26€24k€13k€13k€47k€39k▼ 15.7%
Assets under construction and advance payments27--€25k€0€66k-
Financial fixed assets28€261k€261k€417k€417k€718k▲ 72.3%
Other financial fixed assets284/8---€417k€718k▲ 72.3%
Amounts receivable and cash guarantees285/8---€417k€718k▲ 72.3%
Current assets29/58€15.06M€6.44M€17.44M€27.80M€13.70M▼ 50.7%
Amounts receivable after more than one year29€1.66M€1.47M€2.26M€3.39M€3.16M▼ 6.8%
Other amounts receivable291€1.66M€1.47M€2.26M€3.39M€3.16M▼ 6.8%
Stocks and contracts in progress3---€0€0-
Amounts receivable within one year40/41€1.54M€924k€1.47M€2.39M€2.09M▼ 12.3%
Trade receivables40€89k€80k€417k€292k€106k▼ 63.8%
Other amounts receivable41€1.45M€844k€1.05M€2.10M€1.99M▼ 5.2%
Current investments50/53--€12.50M€20.81M€7.57M▼ 63.6%
Other investments51/53---€20.81M€7.57M▼ 63.6%
Cash at bank and in hand54/58€11.75M€3.93M€1.06M€949k€581k▼ 38.8%
Deferred charges and accrued income490/1€116k€117k€159k€261k€297k▲ 13.8%
Equity and liabilities
Total equity and liabilities10/49€15.92M€7.34M€19.90M€30.36M€16.24M▼ 46.5%
Equity10/15€13.08M€5.29M€16.54M€25.53M€11.45M▼ 55.2%
Contributions10/11€18.06M€18.06M€28.41M€51.96M€51.96M=
Capital10€18.06M€18.06M€28.41M€51.96M€51.96M=
Issued capital100€18.06M€18.06M€28.41M€51.96M€51.96M=
Profit (loss) carried forward14€-4.98M€-12.78M€-11.88M€-26.42M€-40.51M▼ 53.3%
Provisions and deferred taxes16-€9k€0---
Provisions for liabilities and charges160/5-€9k€0---
Other liabilities and charges164/5-€9k€0---
Amounts payable17/49€2.84M€2.04M€3.37M€4.82M€4.80M▼ 0.5%
Amounts payable within one year42/48€1.01M€1.52M€2.44M€2.66M€2.41M▼ 9.3%
Trade debts44€730k€1.18M€1.99M€1.40M€1.76M▲ 25.8%
Suppliers440/4€730k€1.18M€1.99M€1.40M€1.76M▲ 25.8%
Taxes, remuneration and social security45€279k€346k€454k€1.26M€658k▼ 48.0%
Taxes450/3-€26k€419€743k€7k▼ 99.1%
Remuneration and social security454/9€279k€320k€453k€522k€651k▲ 24.7%
Accrued charges and deferred income492/3€1.83M€514k€923k€2.16M€2.38M▲ 10.2%
Line20212022202320242025Change
Profit (loss) for the period9904€-5.83M€-7.79M€-11.88M€-14.54M€-14.09M▲ 3.1%
+ Depreciation and write-downs630€470k€347k€10.00M€12.65M€13.03M▲ 3.0%
Operating cash flow (approximation)€-5.36M€-7.45M€-1.87M€-1.90M€-1.06M▲ 44.2%
Investment in fixed assets (approximation)-€-389k€-11.56M€-12.75M€-13.01M▼ 2.0%
Change in cash-€-7.82M€-2.87M€-109k€-368k▼ 237%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Sign in to download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
21-08
NBB filing Annual accounts filed
fiscal year 2025 · full schema · 21 days late
14-08
State Gazette act Appointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Permanent representative: Pieter-Jan Van Durme · Power of attorney4 facts ▸
  • General meeting, 15/07/2026
  • Auditor appointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
  • Permanent representative, Pieter-Jan Van Durme
  • Power of attorney, Isabel Vercauteren
16-07
State Gazette act Resignations: Innovation Industries Management III B.V., KORYS MANAGEMENT NV and 5 others
Appointments: Innovation Industries Fund III Coöperatief U.A., KORYS MANAGEMENT and 4 others · Permanent representatives: Caaj Douwe GREEBE, David Jacques Martine DEVIGNE and 2 others · Share issue36 facts ▸
  • General meeting, 06-07-2026
  • Share issue, Conversie van 8.075.000 Bevoorrechte A, 16.518.419 Bevoorrechte B en 31.241.852 Bevoorrechte C Aandelen in 55.835.271 Gewone Aandelen
  • Capital increase, €24.100.000,59
  • Share issue, Omgekeerde aandelensplitsing van 124.497.943 Gewone Aandelen en 202.951.844 Bevoorrechte D Aandelen met factor 0,01
  • Capital decrease, €40.508.561
  • Share cancellation, Annulering van 75 Series C Anti-dilutie Warrants en 75 Series C Schadeloosstelling Warrants
  • Share issue, Uitgifte van 45 nieuwe Series D Anti-dilutie Warrants Inschrijvingsrechten
  • Share issue, Uitgifte van 45 nieuwe Series D Schadeloosstelling Warrants
  • Share cancellation, Annulatie van 2.941.635 niet-toegekende ESOP Inschrijvingsrechten en 316.416 vervallen ESOP Inschrijvingsrechten
  • Share issue, Uitgifte van 333.294 ESOP Inschrijvingsrechten in het kader van het Aandelenoptieplan Werknemers 2026
  • Capital, €35.546.749,74
  • Director resignation, Innovation Industries Management III B.V. (director)
  • +24 further facts in this act
30-03
State Gazette act Resignation: Hadyn Parry (director)
Power of attorney3 facts ▸
  • General meeting, 29 januari 2026
  • Director resignation, Hadyn Parry (director)
  • Power of attorney, elke bestuurder van de Vennootschap
2025
29-12
State Gazette act Resignations: Laetitia de Panafieu, Stéphane Roussel and Isabelle Laurencin
Appointments: Hendrik Van Asbroeck, Isabelle Laurencin and 2 others · Mandate compensation11 facts ▸
  • General meeting, 21-05-2025
  • Director resignation, Laetitia de Panafieu (director)
  • Director resignation, Stéphane Roussel (director)
  • Director appointment, Hendrik Van Asbroeck (director)
  • Director appointment, Isabelle Laurencin (director)
  • General meeting, 27-11-2025
  • Director resignation, Isabelle Laurencin (director)
  • Director appointment, Hartmut van Lengerich (director)
  • Director appointment, Stéphane Roussel (director)
  • Mandate compensation, Hartmut van Lengerich
  • Mandate compensation, Stéphane Roussel
20-06
NBB filing Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial Weakest financial yearnet €-14.54M
Net result drops to €-14.54M, the lowest in the series; recovery starts the following year.
31-12
Financial Equity above €25MEq €25.53M ▲54.4%
Equity rises from €16.54M to €25.53M.
06-11
State Gazette act Permanent representatives: Barbara Berckmans, Caaj Greebe and David Devigne
Resignation: Hendrik Van Asbroeck (director) · Appointment: Laetitia de Panafieu (director) · Director confirmation16 facts ▸
  • Board meeting, 17-04-2024
  • Permanent representative, Barbara Berckmans
  • Director resignation, Hendrik Van Asbroeck (director)
  • Director appointment, Laetitia de Panafieu (director)
  • General meeting, 24-04-2024
  • Director confirmation, Laetitia de Panafieu (director)
  • Board composition, Innovation Industries Management III BV (director)
  • Permanent representative, Caaj Greebe
  • Board composition, Korys Management NV (director)
  • Permanent representative, David Devigne
  • Board composition, Agri Investment Fund NV (director)
  • Permanent representative, Barbara Berckmans
  • +4 further facts in this act
18-07
NBB filing Annual accounts filed
fiscal year 2023 · abbreviated schema
12-07
State Gazette act Capital & shares · Statutes amendment
Capital increase · Bank account · Capital10 facts ▸
  • General meeting, 27-06-2024
  • Capital increase, €23.333.333,33
  • Bank account, KBC Bank NV
  • Capital, €51.955.310,15
  • Share cancellation, ESOP inschrijvingsrechten, 1543275
  • Share issue, Aandelenoptieplan Werknemers 2024, ESOP Inschrijvingsrechten
  • Power of attorney, Bestuursorgaan
  • Capital increase
  • Preemption waiver, Individuele afstand van het voorkeurrecht in verband met de kapitaalverhoging door uitgifte van Bevoorrechte C Aandelen
  • Preemption waiver, Individuele afstand van het voorkeurrecht in verband met de uitgifte van ESOP Inschrijvingsrechten
28-02
State Gazette act Capital & shares
Capital increase · Bank account · Capital12 facts ▸
  • General meeting, 31-01-2024
  • Capital increase, €208.333,5
  • Bank account, 30-01-2024
  • Capital, €28.621.976,82
  • Share issue, Series C Anti-Dilutie Warrants, 5
  • Capital increase
  • Share issue, Schadeloosstelling Warrants, 5
  • Share cancellation, ESOP inschrijvingsrechten, 1717371
  • Share issue, Aandelenoptieplan Werknemers 2024, ESOP Inschrijvingsrechten
  • Power of attorney, Aphea.Bio
  • Capital increase
  • Power of attorney, Aphea.Bio
Show earlier events
02-02
State Gazette act Appointments: Deloitte Bedrijfsrevisoren BV (statutory auditor) and Hadyn Parry (director)
Permanent representatives: Pieter-Jan Van Durme, Caaj Creebe and 2 others · Resignation: Johan De Saegher (director)16 facts ▸
  • General meeting, 12-07-2023
  • Auditor appointment, Deloitte Bedrijfsrevisoren BV
  • Permanent representative, Pieter-Jan Van Durme
  • General meeting, 05-12-2023
  • Director resignation, Johan De Saegher (director)
  • Director appointment, Hadyn Parry (director)
  • Board composition, INNOVATION INDUSTRIES MANAGEMENT III BV (director)
  • Permanent representative, Caaj Creebe
  • Board composition, KORYS MANAGEMENT NV (director)
  • Permanent representative, David Devigne
  • Board composition, AGRI INVESTMENT FUND BV (director)
  • Permanent representative, Patrik Haesen
  • +4 further facts in this act
2023
31-12
Financial Equity above €10MEq €16.54M ▲213%
Equity rises from €5.29M to €16.54M.
31-07
State Gazette act Resignations: Willem Broeckaert, Johan Cardoen and 6 others
Appointments: Agri Investment Fund NV, Stéphane Roussel and 5 others · Permanent representatives: Patrik Haesen, Caaj Douwe GREEBE and David Jacques DEVIGNE · Capital increase43 facts ▸
  • General meeting, 20-07-2023
  • Capital increase, €3.072.460,2
  • Capital increase, €20.052.539,8
  • Capital decrease, €12.776.148,83
  • Share issue, 70, Series C Anti-Dilutie Warrants
  • Share issue, 70, Schadeloosstelling Warrants
  • Share issue, 1717371, ESOP Warrants
  • Capital, €28.413.643,32
  • Statutes amendment
  • Director resignation, Willem Broeckaert (director)
  • Director resignation, Johan Cardoen (director)
  • Director resignation, Johan De Saegher (director)
  • +31 further facts in this act
20-07
NBB filing Annual accounts filed
fiscal year 2022 · abbreviated schema
23-01
State Gazette act Miscellaneous
Statutes amendment · Share holding · Correction reference5 facts ▸
  • Statutes amendment
  • Share holding, 971.324 Bevoorrechte B Aandelen en 1.000.000 Bevoorrechte A Aandelen
  • Share holding, 4.166.666 Bevoorrechte B Aandelen
  • Share holding, 3.749.999 Bevoorrechte B Aandelen
  • Correction reference, Akte van 27 juni 2022, gepubliceerd in de Bijlagen bij het Belgisch Staatsblad onder nummer 22343568
2022
05-07
State Gazette act Purpose · Statutes amendment
Purpose change · Power of attorney5 facts ▸
  • General meeting, 27-06-2022
  • Purpose change, Toevoeging in fine van artikel 3: "Eén van de doelen van de Vennootschap is om middels haar bedrijfsvoering en economische activiteiten, een reële positieve imp…
  • Statutes amendment
  • Power of attorney, Aphea.Bio
  • Statutes amendment
04-07
NBB filing Annual accounts filed
fiscal year 2021 · abbreviated schema
12-01
State Gazette act Capital & shares
Capital increase · Capital · Share cancellation9 facts ▸
  • General meeting, 20-12-2021
  • Capital increase, €11.277.400
  • Capital, €18.064.792,15
  • Share cancellation, Aandelenoptieplan Werknemers December 2021, Werknemers Inschrijvingsrechten
  • Share issue, Aandelenoptieplan Werknemers December 2021, Werknemers Inschrijvingsrechten
  • Capital increase
  • Power of attorney, Aphea.Bio
  • Power of attorney, Aphea.Bio
  • Power of attorney, Deloitte Legal - Lawyers BV
2021
31-12
Financial Liquidity doublescurrent ratio 14.92
Current ratio from 6.08 to 14.92.
31-12
Financial Equity above €10MEq €13.08M ▲155%
Equity rises from €5.13M to €13.08M.
29-12
State Gazette act Resignation: Luc Basstanie (director)
Appointment: AIF (director) · Permanent representative: Patrik Haesen · Mandate compensation5 facts ▸
  • Board meeting, 01-09-2021
  • Director resignation, Luc Basstanie (director)
  • Director appointment, AIF (director)
  • Permanent representative, Patrik Haesen
  • Mandate compensation, AIF
17-06
State Gazette act Capital & shares
Capital increase · Bank account · Capital13 facts ▸
  • General meeting, 04-06-2021
  • Capital increase, €500.000
  • Bank account, bijzondere rekening op naam van de Vennootschap bij KBC Bank NV
  • Capital, €6.780.159,75
  • Statutes amendment
  • Share cancellation, Aandelenoptieplan Werknemers 2021, Stock Optie Inschrijvingsrechten
  • Share issue, Klasse B Anti-dilutie Inschrijvingsrechten, 5
  • Capital increase
  • Share issue, Aandelenoptieplan Werknemers 2021 Bis, Stock Optie Inschrijvingsrechten
  • Capital increase
  • Power of attorney, Raad van bestuur van Aphea.Bio
  • Power of attorney, Bestuurder van Aphea.Bio
  • +1 further facts in this act
17-06
State Gazette act Capital & shares
Capital increase · Share issue · Bank account6 facts ▸
  • Board meeting, 01-06-2021
  • Capital increase, €7.232,4
  • Share issue, Gewone Aandelen, 12054
  • Bank account, KBC Bank NV
  • Capital, €6.787.392,15
  • Statutes amendment
03-06
NBB filing Annual accounts filed
fiscal year 2020 · abbreviated schema
13-04
State Gazette act Resignation: DE PANAFIEU Laetitia May Juliette Sybille (director)
Appointment: ROUSSEL Stéphane René Pierre (director) · Capital increase · Capital decrease16 facts ▸
  • General meeting, 30-03-2021
  • Capital increase, €2.000.000
  • Capital decrease, €3.985.967,58
  • Capital, €6.280.159,75
  • Share issue, Klasse B Anti-dilutie Inschrijvingsrechten, 5
  • Share issue, Aandelenoptieplan 2021, Stock Optie Inschrijvingsrechten
  • Director resignation, DE PANAFIEU Laetitia May Juliette Sybille (director)
  • Director appointment, ROUSSEL Stéphane René Pierre (director)
  • Mandate compensation, ROUSSEL Stéphane René Pierre
  • Power of attorney, Deloitte Legal - Lawyers CVBA
  • Statutes amendment
  • Share destruction, Aandelenoptieplan 2020, Stock Optie Inschrijvingsrechten
  • +4 further facts in this act
2020
31-12
Financial Equity above €5MEq €5.13M ▲94.7%
Equity rises from €2.63M to €5.13M.
23-10
State Gazette act Resignation: Jean Emile Léon Joseph VAN NUWENBORG (director)
Reappointments: Willem Frans BROEKAERT, Luc Jozef Maria BASSTANIE and 4 others · Permanent representative: Thomas BEKE · Appointments: Hendrik Kamiel Clemens VAN ASBROECK (nieuwe investeerder bestuurder) and Laetitia May Juliette Sybille DE PANAFIEU (nieuwe investeerder bestuurder)29 facts ▸
  • General meeting, 16-10-2020
  • Capital increase, €2.044.712,33
  • Capital increase, €4.000.000
  • Bank account, BE09 7360 7618 3157
  • Capital decrease, €2.878.585
  • Share issue, Klasse B Anti-dilutie Inschrijvingsrechten, 45
  • Share issue, Stock Optie Inschrijvingsrechten, 598431
  • Director resignation, Jean Emile Léon Joseph VAN NUWENBORG (director)
  • Director reappointment, Willem Frans BROEKAERT (bestaande investeerder bestuurder)
  • Director reappointment, Luc Jozef Maria BASSTANIE (bestaande investeerder bestuurder)
  • Director reappointment, Johan Amede CARDOEN (bestaande investeerder bestuurder)
  • Director reappointment, Participatiemaatschappij Vlaanderen (bestaande investeerder bestuurder)
  • +17 further facts in this act
29-09
State Gazette act Appointments: Johan Desaegher (niet uitvoerend en onafhankelijk bestuurder) and ParticipatieMaatschappij Vlaanderen NV (director)
Resignation: David Devigne (director) · Permanent representatives: Thomas Beke and Veerle Catry · Reappointment: BDO Bedrijfsrevisoren (statutory auditor)15 facts ▸
  • General meeting, 25-04-2018
  • Director appointment, Johan Desaegher (niet uitvoerend en onafhankelijk bestuurder)
  • Power of attorney, Christoph Michiels
  • Power of attorney, Sophie Wyckmans
  • Power of attorney, Vicky Kaluza
  • General meeting, 29-04-2020
  • Director resignation, David Devigne (director)
  • Director appointment, ParticipatieMaatschappij Vlaanderen NV (director)
  • Permanent representative, Thomas Beke
  • Auditor reappointment, BDO Bedrijfsrevisoren (statutory auditor)
  • Permanent representative, Veerle Catry
  • Power of attorney, Christoph Michiels
  • +3 further facts in this act
10-07
NBB filing Annual accounts filed
fiscal year 2019 · abbreviated schema
22-04
State Gazette act Resignation: David Devigne (director)
Appointment: ParticipatieMaatschappij Vlaanderen NV (director) · Permanent representative: Thomas Beke · Mandate compensation5 facts ▸
  • Board meeting, 31-03-2020
  • Director resignation, David Devigne (director)
  • Director appointment, ParticipatieMaatschappij Vlaanderen NV (director)
  • Permanent representative, Thomas Beke
  • Mandate compensation, ParticipatieMaatschappij Vlaanderen NV
2019
29-05
State Gazette act Appointment: Johan De Saegher (independent director)
Capital increase · Bank account · Capital decrease10 facts ▸
  • General meeting, 29-03-2019
  • Capital increase, €2.958.000
  • Bank account, BE54 7340 4679 1997
  • Capital decrease, €3.975.000
  • Capital, €5.100.000
  • Share issue, Employee Stock Option Warrants, 222645
  • Power of attorney, Raad van bestuur
  • Capital increase
  • Director appointment, Johan De Saegher (independent director)
  • Director appointment, Johan De Saegher (chair)
23-05
NBB filing Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
08-05
NBB filing Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
10-07
State Gazette act Resignations: CARDOEN Johan Amede, BROEKAERT Willem Frans and VERCAUTEREN Isabel Julia René
Appointments: VERCAUTEREN Isabel Julia René, CARDOEN Johan Amede and 5 others · Registered-office move · Capital increase20 facts ▸
  • General meeting, 16-06-2017
  • Registered-office move, 9052 Zwijnaarde, Technologiepark 21
  • Capital increase, €300.000
  • Capital increase, €4.437.000
  • Capital, €6.117.000
  • Share issue, Anti-dilutie Warrants, 45
  • Share issue, Employee Stock Optie Warrants, 481495
  • Share issue, Founder Stock Optie Warrants, 280000
  • Director resignation, CARDOEN Johan Amede (director)
  • Director resignation, BROEKAERT Willem Frans (director)
  • Director resignation, VERCAUTEREN Isabel Julia René (director)
  • Director appointment, VERCAUTEREN Isabel Julia René (management bestuurder)
  • +8 further facts in this act
2016
07-12
State Gazette act Incorporation
Appointments: Johan Amede CARDOEN, Willem Frans BROEKAERT and Isabel Julia René VERCAUTEREN · Founding capital · Bank account15 facts ▸
  • Incorporation, 05-12-2016
  • Founding capital, €380.000
  • Bank account, KBC Bank, BE03 7370 4665 1484
  • Director appointment, Johan Amede CARDOEN (director)
  • Director appointment, Willem Frans BROEKAERT (director)
  • Director appointment, Isabel Julia René VERCAUTEREN (director)
  • Mandate compensation, Johan Amede CARDOEN
  • Mandate compensation, Willem Frans BROEKAERT
  • Mandate compensation, Isabel Julia René VERCAUTEREN
  • Inbreng in natura, 100000
  • Inbreng in geld, 140000, 100%
  • Inbreng in geld, 140000, 100%
  • +3 further facts in this act
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
22 of 22 acts read

Directors · office · real estate

Directors
10 directors, no change since 2026
Hartmut Wilhelm VAN LENGERICH
Independent director · since 06-07-2026
Current
KORYS MANAGEMENT
Korys bestuurder · since 06-07-2026 · Public limited company · perm. rep.: David Jacques Martine DEVIGNE
Current
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT
Sfpim bestuurder · since 06-07-2026 · Public limited company · perm. rep.: Peter Paul Johannes Cornelius DE DECKER
Current
Agri Investment Fund NV
Bestaande investeerder bestuurder · since 20-07-2023 · Legal entity · perm. rep.: Patrik Haesen
Current
Korys Management
Nieuwe investeerder bestuurder · since 20-07-2023 · Legal entity · perm. rep.: David Jacques DEVIGNE
Current
Agri Investment Fund
Aif bestuurder · since 30-09-2021 · Private limited company · perm. rep.: Patrik Haesen
Current
4 other directors
Participatiemaatschappij Vlaanderen
Director · since 31-03-2020 · Public limited company · perm. rep.: Thomas Beke
Current
Isabel Julia René VERCAUTEREN
Ceo · since 16-06-2017
Current
Luc Jozef Maria BASSTANIE
Aif bestuurder · since 16-06-2017
Current
Willem Frans BROEKAERT
V bio bestuurder · since 16-06-2017
Current
06-07-2026 Hartmut Wilhelm VAN LENGERICH: Appointed as Independent director
06-07-2026 KORYS MANAGEMENT: Appointed as Korys bestuurder
06-07-2026 SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT: Appointed as Sfpim bestuurder
06-07-2026 Agri Investment Fund: Appointed as Aif bestuurder
06-07-2026 Isabel Julia René VERCAUTEREN: Appointed as Ceo
Full history in the Timeline (61 changes) →
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2016
seat establishment The establishment unit on the map
Ground area
8,776 m²
Building footprint
2,491 m²
Volume, LiDAR
63,128 m³
Parcel 44082B0040/00C000, Flanders · tallest building 29.2 m, ±8 floors. Linked by address, not a title deed.
3 companies at this address See who is registered here
1 establishment unit
Aphea.Bio
Technologiepark-Zwijnaarde 21, 9052 GentManufacture of chemicals and chemical products
since 20162.259.481.970
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
44082B0040/00C000 Flanders 8,776 m² 1 · 2,491 m² 29.1 m · 8 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor
DELOITTE Bedrijfsrevisoren BVCurrent
Statutory auditor · represented by Pieter-Jan Van Durme
01-08-2023 → present
Show 1 earlier auditors
BDO Bedrijfsrevisoren
Statutory auditor · represented by Veerle Catry
succeeded by DELOITTE Bedrijfsrevisoren BV in 2023
16-06-2017 → 01-08-2023

Articles of association

Purpose
De Vennootschap heeft tot voorwerp, in België en in het buitenland, zowel voor eigen rekening als voor rekening van derden, alleen of in participatie met derden: (a) het…
Full purpose

De Vennootschap heeft tot voorwerp, in België en in het buitenland, zowel voor eigen rekening als voor rekening van derden, alleen of in participatie met derden: (a) het exploiteren van biologische, biochemische of andere producten, processen en technologieën in de life sciences sector in het algemeen en in de agrarische sector, inclusief gewasbescherming, naoogstbescherming, gewas-groeibevordering, en gewasverbetering, in het bijzonder. ... (j) het verrichten van alle soorten industriële, financiële en commerciële activiteiten.

according to the deed of 16-07-2026

Structure & network

Connections & network

78 connected companies
Depth
+65 companies via a shared corporate director +65via a sharedcorporate director+2 companies via a shared director +2via a shareddirectorBiotalys, 2 shared directors BBiotalysCitymesh 0G, Shared director C0Citymesh 0GComplix, Shared director CComplixELECTRABEL GREEN PROJECTS FLANDERS, Shared director EGELECTRABELGREEN…VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, Shared director VIVLAAMSINSTITUUT…AMPACIMON, Shared corporate director AAMPACIMONColruyt Group, Shared corporate director CGColruyt GroupNobelwind, Shared corporate director NNobelwindRe-Vive Brownfield Fund II, Shared corporate director RBRe-ViveBrownfield…SMARTMAT, Shared corporate director SSMARTMATVan Marcke Installs & Service, Shared corporate director VMVan MarckeInstalls &…Aphea.Bio Aphea.Bio0666.961.607
Shared directorsBundled connections
This company Company Director Shareholding Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
Biotalys
Shared director
→
Citymesh 0G
Shared director
→
Complix
Shared director
→
Confo Therapeutics
Shared director
→
Show 74 more companies with a shared director
MyCartis
Shared director
→
Aelin Therapeutics
Shared corporate director
→
AMPACIMON
Shared corporate director
→
ASCO INDUSTRIES
Shared corporate director
→
Aviapartner Belgium
Shared corporate director
→
Banqup Group
Shared corporate director
→
Belgian Mobile ID
Shared corporate director
→
Belgian Offshore Platform
Shared corporate director
→
BeLightning
Shared corporate director
→
BELWIND
Shared corporate director
→
BioSenic
Shared corporate director
→
BIOXODES
Shared corporate director
→
BLUE GATE ANTWERP PUBLIC HOLDING
Shared corporate director
→
CALYOS
Shared corporate director
→
CISSOID
Shared corporate director
→
CITYMESH INTEGRATOR
Shared corporate director
→
Colruyt Group
Shared corporate director
→
COMET TRAITEMENTS
Shared corporate director
→
COMET TYRE RECYCLING
Shared corporate director
→
COMETSAMBRE
Shared corporate director
→
DBFM Scholen van Morgen
Shared corporate director
→
De Werkvennootschap
Shared corporate director
→
DEME BLUE ENERGY
Shared corporate director
→
ELECTRAWINDS
Shared corporate director
→
EPICS THERAPEUTICS
Shared corporate director
→
EPIMEDE
Shared corporate director
→
FEops
Shared corporate director
→
Fund+
Shared corporate director
→
GIGARANT
Shared corporate director
→
HERSELF
Shared corporate director
→
HEX - RAYS
Shared corporate director
→
Hubspot Belgium
Shared corporate director
→
iFLUX
Shared corporate director
→
Inbiose
Shared corporate director
→
Indigo Diabetes
Shared corporate director
→
INNOVATION FUND
Shared corporate director
→
InOpSys
Shared corporate director
→
InvestSuite
Shared corporate director
→
LINEAS
Shared corporate director
→
LINEAS GROUP
Shared corporate director
→
Nobelwind
Shared corporate director
→
OncoDNA
Shared corporate director
→
Orizio
Shared corporate director
→
Palais des Congrès
Shared corporate director
→
PARKWIND
Shared corporate director
→
Plopsa Station Antwerp
Shared corporate director
→
PMV - Standaardleningen
Shared corporate director
→
PROMAN Agilitas
Shared corporate director
→
Publiwind
Shared corporate director
→
Re-Vive Brownfield Fund II
Shared corporate director
→
REIN4CED
Shared corporate director
→
RENEWABLE ENERGY BASE OSTEND
Shared corporate director
→
ReWind Therapeutics
Shared corporate director
→
RheaVita
Shared corporate director
→
Sabena Aerospace Engineering
Shared corporate director
→
SMARTMAT
Shared corporate director
→
SmartSec
Shared corporate director
→
SPARKI
Shared corporate director
→
ST Engineering iDirect (Europe) CY
Shared corporate director
→
→
STORM HOLDING 2
Shared corporate director
→
SupplyStack
Shared corporate director
→
THE BELGIAN CHOCOLATE EXPERIENCE
Shared corporate director
→
THEODORUS IV
Shared corporate director
→
TRENDMINER
Shared corporate director
→
Van Marcke Installs & Service
Shared corporate director
→
VIVES II - Louvain Technology Fund
Shared corporate director
→
Vlaams Energiebedrijf
Shared corporate director
→
WANDELAAR INVEST
Shared corporate director
→
ZEPHYR - FIN
Shared corporate director
→

Capital and shareholders

Shareholders according to the acts
After 2 capital increases act of 23-10-2020 ↗
  • V-Bio Fund 1 Arkiv 351,435 shares · 421,721.92 EUR
  • Vlaams Instituut voor Biotechnologie 124,955 shares · 149,945.57 EUR
  • Participatiemaatschappij Vlaanderen (BE 0455.777.660) 170,393 shares · 204,471.23 EUR
  • Biotech Fonds Vlaanderen 170,393 shares · 204,471.23 EUR
  • Gemma Frisius-Fonds K.U. Leuven 106,495 shares · 127,794.52 EUR
  • Qbic II Fund ARKIV 226,480 shares · 271,776.35 EUR
  • Agri Investment Fund 340,785 shares · 408,942.47 EUR
  • Vives II - Louvain Technology Fund 212,991 shares · 255,589.04 EUR

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years
  1. 16-07-2026 Capital increase of 24,100,000.59 EUR · to 76,055,310.74 EUR
  2. 16-07-2026 Capital reduction of 40,508,561 EUR · to 35,546,749.74 EUR · “aanzuivering van geleden verliezen”
  3. 12-07-2024 Capital increase of 23,333,333.33 EUR · to 51,955,310.15 EUR · 15,555,555 new shares
  4. 28-02-2024 Capital increase of 208,333.50 EUR · to 28,621,976.82 EUR · 138,889 new shares
  5. 31-07-2023 Capital increase of 3,072,460.20 EUR · to 21,137,252.35 EUR · 2,179,049 new shares
  6. 31-07-2023 Capital increase of 20,052,539.80 EUR · to 41,189,792.15 EUR · 13,368,359 new shares
  7. 31-07-2023 Capital reduction of 12,776,148.83 EUR · to 28,413,643.32 EUR · “aanzuivering van geleden verliezen”
  8. 12-01-2022 Capital increase of 11,277,400 EUR · to 18,064,792.15 EUR · 9,397,831 new shares
Show 12 older capital entries
  1. 17-06-2021 Capital increase of 7,232.40 EUR · to 6,787,392.15 EUR · 12,054 new shares
  2. 17-06-2021 Capital increase of 500,000 EUR · to 6,780,159.75 EUR · 416,666 new shares
  3. 13-04-2021 Capital increase of 2,000,000 EUR · to 10,266,127.33 EUR · 1,666,666 new shares
  4. 13-04-2021 Capital reduction of 3,985,967.58 EUR · to 6,280,159.75 EUR · “aanzuivering van verliezen en aanleg van reserve”
  5. 23-10-2020 Capital increase of 2,044,712.33 EUR · to 7,144,712.33 EUR · 1,703,927 new shares · in kind
  6. 23-10-2020 Capital increase of 4,000,000 EUR · to 11,144,712.33 EUR · 3,333,329 new shares · in cash
  7. 23-10-2020 Capital reduction of 2,878,585 EUR · to 8,266,127.33 EUR · “ter aanzuivering van de geleden verliezen ten belope van twee miljoen achtenzeventigduizend vijfhonderdvijfentachtig euro (EUR 2.078.585) enerzijds”, “en anderzijds ter aanleg van een reserve ten belope van achthonderdduizend (EUR 800.000) ter dekking van voorzienbare verliezen”
  8. 29-05-2019 Capital increase of 2,958,000 EUR · to 9,075,000 EUR · 2,958,000 new shares · in cash
  9. 29-05-2019 Capital reduction of 3,975,000 EUR · to 5,100,000 EUR · “aanzuivering van overgedragen verliezen per 31/12/2018 en aanleg van reserve”
  10. 10-07-2017 Capital increase of 300,000 EUR · to 1,680,000 EUR · in kind
  11. 10-07-2017 Capital increase of 4,437,000 EUR · to 6,117,000 EUR · in cash
  12. 07-12-2016 Incorporation · 380,000 EUR · 380,000 shares

Public money · subsidies and aid

Flemish government

2022 to 2025 · 18 entries · 4,943,867 EUR awarded · 3,054,549 EUR paid
Year Entries awardedpaid
2025 7 1,290,725 EUR1,097,784 EUR
2024 4 1,899,112 EUR839,503 EUR
2023 3 390,882 EUR58,305 EUR
2022 4 1,363,148 EUR1,058,957 EUR
Schemes
Ontwikkelingsproject
4 entries · 1,891,748 EUR · 1,767,386 EUR paid · Fonds voor Innoveren en Ondernemen
Onderzoeksproject
1 entry · 1,286,240 EUR · 514,000 EUR paid · Fonds voor Innoveren en Ondernemen
Baekeland-mandaat
4 entries · 383,382 EUR · 152,000 EUR paid · Fonds voor Innoveren en Ondernemen
Piloottrajecten bio-gebaseerde toepassingen
2 entries · 93,502 EUR · 93,502 EUR paid · Fonds voor Innoveren en Ondernemen
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
4 entries · 20,201 EUR · 18,253 EUR paid · Fonds voor Innoveren en Ondernemen
Show 1 more
Vlaams opleidingsverlof (VOV)
2 entries · 3,408 EUR · 3,408 EUR paid · Departement Werk en Sociale Economie

Similar companies · same sector, comparable size

Alixar
BE 0693.937.307
Hasselt · Eq €11.33M
PALL ARTELIS
BE 0875.485.178
Hoegaarden · Eq €11.58M
AstriVax Therapeutics
BE 0787.990.881
Leuven · Eq €10.69M
de Duve Institute
BE 0423.837.837
Sint-Lambrechts-Woluwe · Eq €10.57M
SHANT BIOTECH
BE 0680.795.389
Tubize · Eq €10.42M
Of 762 companies in sector 72101 we hold annual accounts for 481. 128 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded05-12-2016
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
20200Manufacture of chemicals and chemical products
Contact
Website www.aphea.bio
E-mail info@aphea.bio
E-mail isabel.vercauteren@aphea.bio

Scores and ratios are computed by Checked and are not a credit decision.

We would like to set cookies. That happens only with your consent. What we measure